# Mereo BioPharma (MREO) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/MREO
## Company Profile
- Ticker: MREO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United Kingdom
- Tags: Immunology
## Stock Data
- Close: 0.3029 USD
- Market cap: 54174555.8946 USD
- Last updated: 2026-08-12
## Business Overview
### Rare Disease Company
Mereo BioPharma develops and partners therapies for rare diseases.
### Setrusumab
Setrusumab is an anti-sclerostin antibody partnered with Ultragenyx for osteogenesis imperfecta. Mereo and its partner are evaluating whether subgroup evidence supports a pediatric regulatory path after global Phase 3 results.
### Vantictumab
Vantictumab is a Wnt-pathway antibody licensed to āshibio for development in autosomal dominant osteopetrosis type 2.
## Why The Stock Is Moving

Following the latest company update, “Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights”, MREO closed up 12.2% at $0.3055 on Aug 11, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Mereo plans to update investors after regulatory discussions regarding a potential pediatric path for setrusumab.
- A Phase 2 study of vantictumab in autosomal dominant osteopetrosis type 2 is expected to begin in the second half of 2026.

## Recent News
- 2026-08-11 12:15 EST — [Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights](https://biopharmsignal.com/news/MREO/mereo-biopharma-reports-second-quarter-2026-financial-results-and-provides-corpo-97032bdf) — Source: Mereo BioPharma
- 2026-08-11 12:00 EST — [Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)](https://biopharmsignal.com/news/MREO/mereo-biopharma-and-sentynl-therapeutics-announce-option-and-license-agreement-f-80f5a2af) — Source: Mereo BioPharma
- 2026-05-12 11:30 EST — [Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates](https://biopharmsignal.com/news/MREO/mereo-biopharma-reports-first-quarter-2026-financial-results-and-provides-corpor-18bef22d) — Source: Mereo BioPharma
- 2026-03-19 12:30 EST — [Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights](https://biopharmsignal.com/news/MREO/mereo-biopharma-reports-full-year-2025-financial-results-and-provides-corporate--69bbe215) — Source: Mereo BioPharma
- 2026-01-12 13:00 EST — [Mereo BioPharma Provides Corporate Update](https://biopharmsignal.com/news/MREO/mereo-biopharma-provides-corporate-update-bfa2a60d) — Source: Mereo BioPharma